Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Intermittent Vancomycin in OPAT
NCT04648696Phase 4Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2021
- Primary completion
- Oct 2022
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vancomycin in bacterial infection (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of Nephrotoxicity in Subjects at week 8. Started Mar 2021; status: terminated.
02
Drugs
vancomycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT04648696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648696.